Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611099 | 1.00 | MAOA (0.43) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10151438 | 0.80 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL20751435 | 0.80 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5878430 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL9488919 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL9489070 | 0.77 | HTR2B (0.46) | MAOAMAOBCALML3HTR2B | |
| SCHEMBL12294536 | 0.77 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14168335 | 0.77 | MAOA (0.44) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL10504741 | 0.76 | CA2 (0.42) | MAOAHTR2B | |
| SCHEMBL9489050 | 0.76 | CA2 (0.42) | MAOAHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2020-07-28 | — | — | US | disclosed |
| US-8017779-B2 | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213356-A1 | Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, IFNG, IRF3 | MAOA 3603/4885MAOB 3460/4885LMNA 3850/4885 |
| US-10723746-B2 | Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases | NQO2, OXA1L, QARS1 | MAOA 2656/4885MAOB 1564/4885LMNA 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.